Showing 1 - 11 results of 11 for search 'L. L. Vysotskaya', query time: 0.07s Refine Results
  1. 1
    LONG-TERM RESULTS OF TARGET THERAPY WITH FIRST AND * SECOND-LINE TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA

    LONG-TERM RESULTS OF TARGET THERAPY WITH FIRST AND * SECOND-LINE TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA by L. L. Vysotskaya, A. K. Golenkov, E. V. Trifonova, T. A. Mitina, E. V. Kataeva, Yu. B. Chernykh

    Published 2016-02-01
    Get full text
    Article
  2. 2
    Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma

    Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma by T. A. Мitinа, A. K. Golenkov, E. V. Trifonova, E. V. Kataeva, L. L. Vysotskaya, Yu. B. Chernykh, S. G. Zakharov, K. A. Belousov, A. V. Karaulov

    Published 2015-12-01
    Get full text
    Article
  3. 3
    The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma

    The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma by T. D. Lutskaya, A. K. Golenkov, T. A. Mitina, I. V. Buravtsova, G. A. Dudina, L. L. Vysotskaya, E. V. Trifonova, E. V. Kataeva, O. V. Moskalets, V. V. Yazdovskiy

    Published 2014-07-01
    Get full text
    Article
  4. 4
    The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma

    The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma by T. D. Lutskaya, A. K. Golenkov, T. A. Mitina, I. V. Buravtsova, G. A. Dudina, L. L. Vysotskaya, E. V. Trifonova, E. V. Kataeva, O. V. Moskalets, V. V. Yazdovskiy

    Published 2014-07-01
    Get full text
    Article
  5. 5
    THE EFFECT OF MULTIDRUG RESISTANCE GENE EXPRESSION ON THE CLINICAL COURSE OF MULTIPLE MYELOMA

    THE EFFECT OF MULTIDRUG RESISTANCE GENE EXPRESSION ON THE CLINICAL COURSE OF MULTIPLE MYELOMA by Yu. B. Chernykh, A. K. Golenkov, S. S. Shushanov, T. A. Kravtsova, E. Yu. Rybalkina, A. F. Karamysheva, T. A. Mitina, E. V. Trifonova, E. V. Kataeva, L. L. Vysotskaya, A. A. Stavrovskaya

    Published 2017-01-01
    Get full text
    Article
  6. 6
    Treatment of patients with refractory chronic lymphocytic leukemia with alemtuzumab, alone or in combination with fludarabine

    Treatment of patients with refractory chronic lymphocytic leukemia with alemtuzumab, alone or in combination with fludarabine by E. V. Kataeva, A. K. Golenkov, E. V. Trifonova, G. A. Dudina, T. A. Mitina, L. L. Vysotskaya, T. D. Lutskaya, I. V. Buravtsova, R. V. Gorenkov, Yu. Yu. Chuksina, V. V. Yazdovskiy

    Published 2014-07-01
    Get full text
    Article
  7. 7
    Treatment efficacy of chronic myeloid leukemia with imatinib in clinical practice

    Treatment efficacy of chronic myeloid leukemia with imatinib in clinical practice by A. K. Golenkov, L. L. Vysotskaya, E. V. Trifonova, T. A. Mitina, T. D. Lutskaya, E. V. Kataeva, G. A. Dudina, Yu. B. Chernykh, I. V. Buravtsova, A. N. Gurov, R. V. Gorenkov

    Published 2014-07-01
    Get full text
    Article
  8. 8
    Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma

    Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma by K. A. Belousov, T. A. Mitina, Yu. Yu. Chuksina, A. K. Golenkov, E. V. Kataeva, E. V. Trifonova, Yu. B. Chernykh, L. L. Vysotskaya, S. G. Zakharov, E. F. Klinushkina, A. N. Mitin

    Published 2019-04-01
    Get full text
    Article
  9. 9
    Treatment efficacy of chronic myeloid leukemia with imatinib in clinical practice

    Treatment efficacy of chronic myeloid leukemia with imatinib in clinical practice by A. K. Golenkov, L. L. Vysotskaya, E. V. Trifonova, T. A. Mitina, T. D. Lutskaya, E. V. Kataeva, G. A. Dudina, Yu. B. Chernykh, I. V. Buravtsova, A. N. Gurov, R. V. Gorenkov

    Published 2014-07-01
    Get full text
    Article
  10. 10
    Treatment of patients with refractory chronic lymphocytic leukemia with alemtuzumab, alone or in combination with fludarabine

    Treatment of patients with refractory chronic lymphocytic leukemia with alemtuzumab, alone or in combination with fludarabine by E. V. Kataeva, A. K. Golenkov, E. V. Trifonova, G. A. Dudina, T. A. Mitina, L. L. Vysotskaya, T. D. Lutskaya, I. V. Buravtsova, R. V. Gorenkov, Yu. Yu. Chuksina, V. V. Yazdovskiy

    Published 2014-07-01
    Get full text
    Article
  11. 11
    Expression levels of the apoptosis genes FAS, TNFR2, TRAIL, DR3 and DR4/5 in patients with newly diagnosed chronic lymphatic leukemia before and after treatment with fludarabine, cyclophosphamide and rituximab (FCR)

    Expression levels of the apoptosis genes FAS, TNFR2, TRAIL, DR3 and DR4/5 in patients with newly diagnosed chronic lymphatic leukemia before and after treatment with fludarabine, c... by S. G. Zakharov, A. K. Golenkov, V. A. Misyurin, E. V. Kataeva, M. A. Baryshnikova, Yu. Yu. Chuksina, T. A. Mitina, E. V. Trifonova, L. L. Vysotskaya, Yu. B. Chernykh, E. F. Klinushkina, K. A. Belousov, Yu. P. Finashutina, A. V. Misyurin

    Published 2018-12-01
    Get full text
    Article

Search Tools: